Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Hormone-free solution for vaginal atrophy

Project description

A device for safer vaginal atrophy treatment

Vaginal atrophy is a globally challenging disease for 80 % of menopausal women and breast cancer survivors. It is associated with thinning, inflammation of the vaginal walls due to lower oestrogen levels. Current treatment options: hormone therapy and moisturisers are poorly tolerated due to side effects and safety concerns. The EIC-funded AVeta project has developed a revolutionary device that is hormone-free, natural, safe, affordable and suitable for all women suffering from vaginal atrophy. Treatment provides long-lasting symptom relief and as it is based on the body’s natural healing response, presents with no side effects. It will be clinically prescribed in an outpatient setting and can then be self-administered monthly by patients in the comfort of their homes.

Objective

Vaginal Atrophy (VA) is a chronic and progressive condition. VA impacts on the quality of life, relationships, everyday activities and confidence of women sufferers. It is associated with thinning, drying and inflammation of the vaginal tissue. It is experienced by 80% of all women globally and is the most common symptom of the menopause. Over 70% of Breast Cancer Survivors will also suffer from VA due to side effects of chemotherapy and the cancer-blocker drugs they take further exacerbate symptoms of VA. Current treatment options for VA, primarily pharmaceuticals are either ineffective or poorly tolerated. In the EU and US, 3.6m patients of VA reject existing treatments.
AVeta- a medical device delivering the only hormone free, affordable and safe targeted therapy for all women suffering from VA. Solution is based on pathophysiology of wound healing and will be prescribed by a Clinician in an outpatient setting and women will self-administer the therapy monthly at home.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2021-ACCELERATOROPEN-01

See all projects funded under this call

Coordinator

AVETA MEDICAL LIMITED
Net EU contribution
€ 2 500 000,00
Address
BRIAN LEDWITH CAHERNASHILLEENY CLAREGALWAY
H91 TRX7 Galway
Ireland
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 814 567,50